Published in Front Immunol on July 26, 2017
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Immunity, inflammation, and cancer. Cell (2010) 28.27
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature (2008) 10.73
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2012) 10.47
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Melanoma. N Engl J Med (2006) 8.80
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Identification of cells initiating human melanomas. Nature (2008) 8.28
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science (2012) 7.08
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 4.35
Roles of TGFbeta in metastasis. Cell Res (2009) 4.35
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33
The epidemiology of skin cancer. Br J Dermatol (2002) 4.07
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 3.80
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.92
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab (2016) 2.88
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 2.86
Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med (2004) 2.78
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63
The impact of PEGylation on biological therapies. BioDrugs (2008) 2.55
Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol (2010) 2.44
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res (2014) 2.27
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity. Cell (2017) 2.06
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell (2016) 2.00
Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 1.99
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell (2014) 1.98
Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene (2008) 1.93
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res (2011) 1.89
Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell (2014) 1.88
Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol (2013) 1.85
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell (2013) 1.82
Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov (2014) 1.80
Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1.74
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Isosensitization to the U factor. J Am Med Assoc (1959) 1.68
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep (2015) 1.67
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer (2009) 1.62
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci U S A (2013) 1.53
Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene (2002) 1.50
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature (2016) 1.30
Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol (2011) 1.26
Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood (2010) 1.26
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol (2013) 1.21
Inflammation-driven carcinogenesis is mediated through STING. Nat Commun (2014) 1.19
Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med (2014) 1.17
Mechanism of the antitumour effect of interferon in mice. Nature (1972) 1.17
Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene (2000) 1.14
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol (2010) 1.12
Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol (2013) 1.12
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol (2013) 1.11
Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res (2012) 1.09
Tissue interactions in neural crest cell development and disease. Science (2013) 1.08
Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 1.08
Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol (2014) 1.07
Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis (2011) 1.05
Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother (2012) 1.05
Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe (2013) 1.03
Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res (1984) 1.03
Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. Cell Rep (2015) 1.03
Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol (2014) 1.02
APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol (2010) 1.00
Diverse roles of STING-dependent signaling on the development of cancer. Oncogene (2015) 0.98
Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget (2015) 0.98
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clin Cancer Res (2016) 0.98
Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS One (2015) 0.97
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res (2006) 0.97
CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol (2013) 0.95
Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol (2002) 0.95
Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int J Cancer (1978) 0.95
Activation of a CrkL-stat5 signaling complex by type I interferons. J Biol Chem (1999) 0.94
Toll receptor families: structure and function. Semin Immunol (2004) 0.94
IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene (1997) 0.94
Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer (2004) 0.93
ΔNp63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis. Oncotarget (2016) 0.87